Toshiyuki Kobayashi

Toshiyuki Kobayashi

Auto-generated profile, based on publicly available information

Toshiyuki Kobayashi

Department of Radiobiology, Institute for Environmental Sciences

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2010 in Journal of Medical Genetics
Verified
Journal Article
Open access
PDF file
MKMakiko Kunogi
Makiko Kunogi
MKMasatoshi Kurihara
Masatoshi Kurihara
TITakako Shigihara Ikegami
Takako Shigihara Ikegami
TKToshiyuki Kobayashi
Toshiyuki Kobayashi
NSNoriko Shindo
Noriko Shindo
KSKuniaki Seyama
Kuniaki Seyama
Background: Birt–Hogg–Dubé syndrome (BHDS) is an inherited autosomal genodermatosis characterised by fibrofolliculomas of the skin, renal tumours and multiple lung cysts. Genetic studies have disclosed that the clinical picture as well as responsible germline FLCN mutations are diverse. Objectives: BHDS may be caused by a germline deletion which cannot be detected by a conventional genetic approach. Real-time quantitative polymerase chain reaction (qPCR) may be able to identify such a mutation and thus provide us with a more accurate clinical picture of BHDS. Methods: This study analysed 36 patients with multiple lung cysts of undetermined causes. Denaturing high performance liquid chromatography (DHPLC) was applied for mutation screening. If no abnormality was detected by DHPLC, the amount of each FLCN exon in genome was quantified by qPCR. Results: An FLCN germline mutation was found in 23 (63.9%) of the 36 patients by DHPLC and direct sequencing (13 unique small nucleotide alterations which included 11 novel mutations). A large genomic deletion was identified in two of the remaining 13 patients by qPCR (one patient with exon 14 deletion and one patient with a deletion encompassing exons 9 to 14). Mutations including genomic deletions were most frequently identified in the 3′-end of the FLCN gene including exons 12 and 13 (13/25=52.0%). The BHDS patients whose multiple cysts prompted the diagnosis in this study showed a very low incidence of skin and renal involvement. Conclusions: BHDS is due to large deletions as well as small nucleotide alterations. Racial differences may occur between Japanese and patients of European decent in terms of FLCN mutations and clinical manifestations.

11 February 2021 in Molecular Cancer Research
Verified
Journal Article
Open access
PDF file
TSTatsuhiro Sato
Tatsuhiro Sato
SMSatomi Mukai
Satomi Mukai
HIHaruna Ikeda
Haruna Ikeda
EMEmi Mishiro-Sato
Emi Mishiro-Sato
KAKen Akao
Ken Akao
YSYoshitaka Sekido
Yoshitaka Sekido
Malignant mesothelioma (MM) is an aggressive tumor that typically develops after a long latency following asbestos exposure. Although mechanistic target of rapamycin complex 1 (mTORC1) activation enhances MM cell growth, the mTORC1 inhibitor everolimus has shown limited efficacy in clinical trials of MM patients. We explored the mechanism underlying mTORC1 activation in MM cells and its effects on cell proliferation and progression. Analysis of the expression profiles of 87 MMs from The Cancer Genome Atlas revealed that 40 samples (46%) displayed altered expression of RPTOR (mTORC1 component) and genes immediately upstream that activate mTORC1. Among them, we focused on RHEB and RHEBL1, which encode direct activators of mTORC1. Exogenous RHEBL1 expression enhanced MM cell growth, indicating that RHEB–mTORC1 signaling acts as a pro-oncogenic cascade. We investigated molecules that directly activate RHEBs, identifying SmgGDS as a novel RHEB-binding protein. SmgGDS knockdown reduced mTORC1 activation and inhibited the proliferation of MM cells with mTORC1 activation. Interestingly, SmgGDS displayed high binding affinity with inactive GDP-bound RHEBL1, and its knockdown reduced cytosolic RHEBL1 without affecting its activation. These findings suggest that SmgGDS retains GDP-bound RHEBs in the cytosol, whereas GTP-bound RHEBs are localized on intracellular membranes to promote mTORC1 activation. We revealed a novel role for SmgGDS in the RHEB–mTORC1 pathway and its potential as a therapeutic target in MM with aberrant mTORC1 activation. Implications: Our data showing that SmgGDS regulates RHEB localization to activate mTORC1 indicate that SmgGDS can be used as a new therapeutic target for MM exhibiting mTORC1 activation.

3 April 2023
Verified
Other
Open access
TSTatsuhiro Sato
Tatsuhiro Sato
SMSatomi Mukai
Satomi Mukai
HIHaruna Ikeda
Haruna Ikeda
EMEmi Mishiro-Sato
Emi Mishiro-Sato
KAKen Akao
Ken Akao
YSYoshitaka Sekido
Yoshitaka Sekido
Figure S1. RHEB mRNA expression in different types of cancer. Figure S2. In vivo growth of MeT-5A mesothelial cells expressing exogenous RHEBL1. Figure S3. RHEBL1 binds to SmgGDS. Figure S4. SmgGDS knockdown suppresses the proliferation of mesothelial cells expressing exogenous RHEBL1. Figure S5. SmgGDS knockdown suppresses the growth of PTEN-deficient MM cells in vitro. Figure S6. Subcellular RHEBL1 localization. Figure S7. SmgGDS knockdown alters RHEBL1 localization in PTEN-deficient MM cells. Figure S8. Amino acid stimulation does not affect RHEBL1 subcellular localization. Figure S9. RHEBL1 farnesylation is essential for SmgGDS binding.

3 April 2023
Verified
Other
Open access
TSTatsuhiro Sato
Tatsuhiro Sato
SMSatomi Mukai
Satomi Mukai
HIHaruna Ikeda
Haruna Ikeda
EMEmi Mishiro-Sato
Emi Mishiro-Sato
KAKen Akao
Ken Akao
YSYoshitaka Sekido
Yoshitaka Sekido
Figure S1. RHEB mRNA expression in different types of cancer. Figure S2. In vivo growth of MeT-5A mesothelial cells expressing exogenous RHEBL1. Figure S3. RHEBL1 binds to SmgGDS. Figure S4. SmgGDS knockdown suppresses the proliferation of mesothelial cells expressing exogenous RHEBL1. Figure S5. SmgGDS knockdown suppresses the growth of PTEN-deficient MM cells in vitro. Figure S6. Subcellular RHEBL1 localization. Figure S7. SmgGDS knockdown alters RHEBL1 localization in PTEN-deficient MM cells. Figure S8. Amino acid stimulation does not affect RHEBL1 subcellular localization. Figure S9. RHEBL1 farnesylation is essential for SmgGDS binding.

3 April 2023
Verified
Other
Open access
TSTatsuhiro Sato
Tatsuhiro Sato
SMSatomi Mukai
Satomi Mukai
HIHaruna Ikeda
Haruna Ikeda
EMEmi Mishiro-Sato
Emi Mishiro-Sato
KAKen Akao
Ken Akao
YSYoshitaka Sekido
Yoshitaka Sekido
Malignant mesothelioma (MM) is an aggressive tumor that typically develops after a long latency following asbestos exposure. Although mechanistic target of rapamycin complex 1 (mTORC1) activation enhances MM cell growth, the mTORC1 inhibitor everolimus has shown limited efficacy in clinical trials of MM patients. We explored the mechanism underlying mTORC1 activation in MM cells and its effects on cell proliferation and progression. Analysis of the expression profiles of 87 MMs from The Cancer Genome Atlas revealed that 40 samples (46%) displayed altered expression of RPTOR (mTORC1 component) and genes immediately upstream that activate mTORC1. Among them, we focused on RHEB and RHEBL1, which encode direct activators of mTORC1. Exogenous RHEBL1 expression enhanced MM cell growth, indicating that RHEB–mTORC1 signaling acts as a pro-oncogenic cascade. We investigated molecules that directly activate RHEBs, identifying SmgGDS as a novel RHEB-binding protein. SmgGDS knockdown reduced mTORC1 activation and inhibited the proliferation of MM cells with mTORC1 activation. Interestingly, SmgGDS displayed high binding affinity with inactive GDP-bound RHEBL1, and its knockdown reduced cytosolic RHEBL1 without affecting its activation. These findings suggest that SmgGDS retains GDP-bound RHEBs in the cytosol, whereas GTP-bound RHEBs are localized on intracellular membranes to promote mTORC1 activation. We revealed a novel role for SmgGDS in the RHEB–mTORC1 pathway and its potential as a therapeutic target in MM with aberrant mTORC1 activation.Implications:Our data showing that SmgGDS regulates RHEB localization to activate mTORC1 indicate that SmgGDS can be used as a new therapeutic target for MM exhibiting mTORC1 activation.

3 June 2026 in International Journal of Radiation Biology
Verified
Journal Article
Closed access
TKTetsuhiro Kinugawa
Tetsuhiro Kinugawa
ITIgnacia Tanaka
Ignacia Tanaka
STSatoshi Tanaka
Satoshi Tanaka
TWTakahiro Wada
Takahiro Wada
TKToshiyuki Kobayashi
Toshiyuki Kobayashi
Using experimental data from the lifespan study conducted at the Institute for Environmental Sciences on female B6C3F1 mice exposed in utero, the effect of radiation exposure in utero on cancer was analyzed using a mathematical model focusing on the effect of radiation on the occurrence of cancer; progression of cancer over time; and death due to cancer. Data used for analysis were extracted from the in utero lifespan experiment (non-irradiated controls and irradiated group, 400 mGy/day x18 days) including: age at death, cause of death, and neoplasm(s) observed at the time of death. The new method based on our mathematical model, was introduced to evaluate the temporal change in the cancer incidence rate and focused on competing risks between different cancers such as malignant lymphomas and solid cancers. To validate the new method, we compared it to our previous analysis. The analysis showed that in utero exposure shortened the mean life expectancy due to solid cancer by 199.4 days whereas that of malignant lymphoma was not significantly affected by the exposure. There was also no change in the mean age at occurrence and progression (time between occurrence until it caused death) for malignant lymphomas. For solid cancers, the mean age at the occurrence was shortened by 185.7 days whereas the progression period remained unchanged.